Isentress
NDC Package 76519-1130-6
Package Information
Isentress is adult Patients:ISENTRESS® and ISENTRESS® HD are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients.Pediatric Patients:ISENTRESS is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients 4 weeks of age and older.ISENTRESS HD is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in pediatric patients weighing at least 40 kg. Marketed by H.j. Harkins Company Inc., this product is identified by NDC 76519-1130 and is authorized under FDA application NDA022145.
Identification & Billing
- RxCUI: 744842 - raltegravir 400 MG Oral Tablet
- RxCUI: 744842 - raltegravir 400 MG (as raltegravir potassium 434.4 MG) Oral Tablet
- RxCUI: 744846 - Isentress 400 MG Oral Tablet
- RxCUI: 744846 - raltegravir 400 MG Oral Tablet [Isentress]
- RxCUI: 744846 - ISENTRESS 400 MG (as raltegravir potassium 434.4 MG) Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 76519 - H.j. Harkins Company Inc.
- 76519-1130 - Isentress
- 76519-1130-6 - 6 TABLET, FILM COATED in 1 VIAL
- 76519-1130 - Isentress
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 76519-1130-6 identifies a specific commercial package of 6 tablet, film coated in 1 vial of Isentress, labeled by H.j. Harkins Company Inc.. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by H.j. Harkins Company Inc. on July 31, 2017. The current certification is valid through December 31, 2019.
How is this H.j. Harkins Company Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 76519113006. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.